NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantum BioPharma's Market Manipulation Allegations and CTV W5 Coverage
TL;DR
Quantum BioPharma's lawsuit against CIBC and RBC could expose market manipulation, potentially strengthening its position for advancing Lucid-MS and creating investment opportunities.
Quantum BioPharma alleges stock spoofing through millions of illegal orders from bank platforms, detailed in a CTV W5 segment and a $700 million lawsuit.
By pursuing legal action against alleged market manipulation, Quantum BioPharma aims to protect its development of Lucid-MS, a potential multiple sclerosis treatment that could improve lives.
CTV's W5 aired Part 2 investigating Quantum BioPharma's claims of widespread stock spoofing tied to its $700 million lawsuit against major Canadian banks.
Found this article helpful?
Share it with your network and spread the knowledge!
The article covers CTV News' W5 program airing Part 2 of a three-part series examining Quantum BioPharma's allegations of stock spoofing and market manipulation, which are part of the company's $700 million lawsuit against CIBC and RBC.
The coverage highlights Quantum BioPharma's claims of widespread market manipulation and its impact on the company's efforts to advance Lucid-MS, a potential multiple sclerosis treatment, bringing public attention to their legal allegations.
Quantum BioPharma Ltd. (CEO Zeeshan Saeed and Co-Executive Chair Anthony Durkacz), CTV News' W5 program with journalist Jon Woodward, and the banks CIBC and RBC who are defendants in the $700 million lawsuit.
The company cites Canadian exchange data that points to millions of purportedly illegal orders originating from bank platforms, as mentioned in their lawsuit.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for treating neurodegenerative and metabolic disorders, alcohol misuse disorders, with its lead compound being Lucid-MS for multiple sclerosis.
Lucid-MS is Quantum BioPharma's patented new chemical entity shown to prevent and reverse myelin degradation (the underlying mechanism of multiple sclerosis) in preclinical models, representing their most advanced drug candidate.
unbuzzd(TM) is a product invented by Quantum BioPharma; they spun out its OTC version to Unbuzzd Wellness Inc., retaining 20.11% ownership (as of March 31, 2025) and receiving royalty payments of 7% of sales until $250 million is reached, then 3% in perpetuity.
The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
Quantum BioPharma has filed a $700 million lawsuit against CIBC and RBC alleging stock spoofing and market manipulation activities that have impacted the company.
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising, as indicated in the disclaimer at the beginning of the content.
Curated from InvestorBrandNetwork (IBN)
